Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

365607 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 03/08/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 03/08/2021.
Displaying: 860 trials in your specialties ()
View trials across your selected specialties

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Lymphoma, Follicular
View Full Trial
INTERVENTION

Drug: R-MANT, Drug: R2-MANT

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

AO Niguarda Ca' Granda, Milano, MI, Italy

Brief Summary

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Leukemia
View Full Trial
INTERVENTION

Drug: Lenalidomide, Drug: Rituximab, Drug: Fludarabine, Drug: Cyclophosphamide, Procedure: NK Cells, Drug: Cytarabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Brief Summary

The goal of this clinical research study is to find the highest tolerable dose of immune cells called natural killer (NK) cells that can be given with chemotherapy to patients with CLL. Researchers want to learn if adding NK cells will be effective in treating the disease. The safety of this will also be studied. NK cells may kill cancer cells that remain in your body after your last chemotherapy treatment. The NK cells will be separated from umbilical cord blood. The device used in the laboratory to separate the NK cells is called a CliniMACS. These separated NK cells will then be grown in the lab to increase the number of NK cells that can be given to you by vein. This is an investigational study. Rituximab, fludarabine, and cyclophosphamide are FDA approved and commercially available for the treatment of CLL. Cytarabine, filgrastim, and lenalidomide are FDA approved and commercially available for the treatment of other types of cancer. The use of cytarabine, filgrastim, and lenalidomide for the treatment of CLL is investigational. The use of NK cells is investigational. The NK cell process is not FDA approved or commercially available. It is currently being used for research purposes only. Up to 44 patients will take part in this study. All will be enrolled at MD Anderson.

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Lenalidomide, Drug: Dexamethasone, Biological: Elotuzumab (BMS-901608)

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Local Institution, Hamamatsu-shi, Shizuoka, Japan

Brief Summary

The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Pla...
View Full Trial
INTERVENTION

Biological: Incomplete Freund's Adjuvant, Other: Laboratory Biomarker Analysis, Drug: Lenalidomide, Biological: Sargramostim, Biological: SVN53-67/M57-KLH Peptide Vaccine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Roswell Park Cancer Institute, Buffalo, New York, United States

Brief Summary

This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide maintenance therapy. Vaccines made from survivin peptide may help the body build an effective immune response to kill cancer cells that express survivin. Incomplete Freund's adjuvant may help stimulate the body's immune response to a vaccine treatment. Colony-stimulating factors, such as sargramostim, may increase the production of blood cells. Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant and sargramostim before or after the start of lenalidomide maintenance therapy may be a better treatment for multiple myeloma.

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Carfilzomib/Lenalidomide/Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

CHU de Toulouse, Toulouse, France

Brief Summary

The purpose is to determine whether induction and consolidation treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further investigation in clinical trials.

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Smoldering Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Ixazomib, Drug: Lenalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Brief Summary

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Plasmacytoma, POEMS Syndrome
View Full Trial
INTERVENTION

Drug: Dexamethasone, Drug: Ixazomib Citrate, Other: Laboratory Biomarker Analysis, Drug: Lenalidomide, Other: Questionnaire Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic, Rochester, Minnesota, United States

Brief Summary

This pilot clinical trial studies how well ixazomib citrate, lenalidomide, and dexamethasone work in treating patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib citrate, lenalidomide, and dexamethasone may work better in treating patients with POEMS syndrome.

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Pembrolizumab, Drug: Lenalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

John Theurer Cancer Center-Hackensack Meridian Health, Hackensack, New Jersey, United States

Brief Summary

This is an open-label, Phase II, single center trial of pembrolizumab (MK-3475), lenalidomide and dexamethasone in subjects with high risk Multiple Myeloma (hrMM) post high-dose chemotherapy with autologous stem cell transplantation (ASCT). Patients with high-risk MM defined as those with one of the following abnormalities who have undergone induction therapy followed by single or tandem melphalan -based ASCT will be considered eligible.

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    LYMPHOMA
View Full Trial
INTERVENTION

Drug: Durvalumab, Drug: Lenali

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

National University Hospital Singapore, Singapore, Singapore

Brief Summary

This is a multi-center, open-label, phase II study of durvalumab in combination with lenalidomide for treatment of relapsed/refractory NK/T-cell lymphoma (NKTCL). The study will employ a 2-stage Simon Optimal design with 80% power and type 1 error rate (significance level) of 5%. Stage 1 will involve 8 patients and will require at least 2 patients to achieve the primary end point of overall response in order to proceed onto to stage 2, which will have a target enrolment of 14 patients.

Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Multiple Myeloma
View Full Trial
INTERVENTION

Drug: Isatuximab, Drug: Carfilzomib, Drug: Lenalidomide, Drug: Dexamethasone

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Vivantes Am Urban, Berlin, Germany

Brief Summary

A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients